Atlas Venture partner Bruce Booth predicted on STAT’s podcast that biotech IPO activity will rebound in 2026 after a two-year drought, forecasting a wave of public listings as market appetite returns. Booth based his expectation on improving public-market conditions and data inflection points that typically trigger IPO windows for drug developers. That sentiment is mirrored by year-end market performance: StockWatch analysis shows major biotech ETFs like IBB and XBI rose strongly in 2025, signaling investor interest in the sector. If market momentum continues, private biotechs nearing key clinical readouts could accelerate IPO plans, while investors and bankers prepare for renewed deal flow.